News

Search:

Pfizer's Tofacitinib Wins Regulatory Approval Ahead of PDUFA Date

0 Likes

After a lengthy back and forth, Pfizer’s potential rheumatoid arthritis blockbuster Xeljanz (tofacatinib) has won approval from the US Food and Drug Administration (FDA), the agency announced on 6 Read More...

Tags:

Blockbuster

Pfizer

Rheumatoid Arthritis

Tofacitinib

Xeljanz

Pfizer Withdraws Indication for RA Drug After It Fails to Complete Required Study

0 Likes

The US Food and Drug Administration (FDA) said Pfizer is withdrawing an indication for its rheumatoid arthritis (RA) drug Celebrex after Pfizer indicated it would not be able to complete a mandated Read More...

Tags:

Accelerated Approval

Arthritis

Celebrex

FDA

Osteoarthritis

Pfizer

Rheumatoid Arthritis

Withdrawal

Merck Settles Vioxx Criminal Charges With US for $322 Million

0 Likes

US pharmaceutical manufacturer Merck & Co. has settled criminal charges over the company’s marketing of its painkiller drug Vioxx, reports Bloomberg.Merck will pay a $321.6 million criminal fine after Read More...

Tags:

$322 Million

Arthritis

Charges

Criminal

Department of Justice

FDA

Illegal

Merck

Rheumatoid Arthritis

Vioxx

Report: Pharma-Funded Science Not Necessarily Biased Towards Drugmakers

0 Likes

A report published in the journal Arthritis & Rheumatism showed no statistical significance between arthritis research funded by pharmaceutical manufacturers and research funded by non-profits or Read More...

Tags:

Bias

Clinical Trials

Journal

Positive

Publishing

report

Rheumatoid Arthritis

Study

Trials

RF Today is Regulatory Focus' daily news brief. Each edition contains the top global regulatory news stories about pharmaceuticals, medical devices, biotechnology and more. Learn more

Most Viewed
Most Popular

Most Viewed

FDA Plans Huge Cardiovascular Registry With Focus on Medical Devices 2 April 2013
In Unprecedented Shift, EU Parliament Proposes Premarket Authorization for Medical Devices 15 April 2013
Goodbye, KFDA: Korean Regulator Gets New Name, Decentralized Authority After Reorganization 28 March 2013
FDA Gets Go-Ahead for Study of DTC Advertising and Social Media 18 April 2013
UPDATED: President's Budget Proposal Calls for Small Increases at FDA, but Big Changes for Industry 11 April 2013
IBM Awarded Huge Contract to Modernize Regulatory Review Processes at FDA 29 April 2013
New FDA Document Clarifies IND Process for Drugs, Biologics and Biosimilars 30 April 2013
Warning Letter to Company Cites Low Supplies of Toilet Paper 15 May 2013

New Regulatory Focus Apps for iPad and iPhone

Stay Connected:

Regulatory Focus is for regulatory professionals written by regulatory professionals.

The publication takes a look at the important topics facing regulatory professionals in a changing global healthcare landscape. From topics ranging from research and development to labeling and marketing, the articles try to analyze, inform, and educate readers about the issues at the forefront of the industry.

Rated as the number one benefit by the members of RAPS, Regulatory Focus strives to provide the best and most current information to regulatory professionals so they can succeed and advance at every stage in their careers.

For questions or comments on our content or to find out more about Regulatory Focus, please visit our About RF page.

News

Pfizer's Tofacitinib Wins Regulatory Approval Ahead of PDUFA Date

Pfizer Withdraws Indication for RA Drug After It Fails to Complete Required Study

Merck Settles Vioxx Criminal Charges With US for $322 Million

Report: Pharma-Funded Science Not Necessarily Biased Towards Drugmakers

Get RF Today